Search
Upadacitinib
go.drugbank.com/drugs/DB15091ApprovedInvestigational[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration.[L10896]. … [A189171] The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid
Quizartinib
go.drugbank.com/drugs/DB12874ApprovedInvestigational[A260641] Quizartinib was approved by the FDA in July 2023 and developed under the brand name VANFLYTA by Daiichi Sankyo. … Quizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug developed specifically targeting FLT3, as other agents with FLT3 inhibition activities were investigated
Dienogest
go.drugbank.com/drugs/DB09123ApprovedInvestigationalDienogest is commonly marketed as Visanne, Natazia and Qlaira. … It is primarily used as a contraceptive in combination with ethinylestradiol, or in other combination form pills approved in United States and Europe however it is not available in the US by itself.
Darvadstrocel
go.drugbank.com/drugs/DB16581ApprovedInvestigationalWithdrawn[A244524] Darvadstrocel was first approved by the European Commission on March 23, 2018, under the brand name Alofisel. … Perianal fistula is a common manifestation of Crohn’s disease and is often difficult to manage, as it may be associated with complex presentations and symptoms.
Axicabtagene ciloleucel
go.drugbank.com/drugs/DB13915ApprovedInvestigationalIt is marketed under the brand name Yescarta and is used to treat large B-cell lymphomas and follicular lymphoma in adults. … The drug has a unique mechanism of action, as it utilizes the patient's own T cells, which play a central role in immune response to cancer.
Trastuzumab emtansine
go.drugbank.com/drugs/DB05773ApprovedInvestigationalTrastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic … Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity.
Zuclopenthixol
go.drugbank.com/drugs/DB01624ApprovedInvestigationalMajor brands of zuclopenthixol are Cisordinol, Acuphase, and Clopixol. This drug is a liquid. This compound belongs to the thioxanthenes. … Zuclopenthixol, also known as Zuclopentixol or Zuclopenthixolum, is an antipsychotic agent.
Relugolix
go.drugbank.com/drugs/DB11853ApprovedInvestigationalIt was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids,[A225816] and more recently by the United States' FDA in 2020, under the brand name … [A225761] Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist approved for the treatment of prostate cancer - similar therapies such as [degarelix] require subcutaneous
Riociguat
go.drugbank.com/drugs/DB08931ApprovedInvestigationalRiociguat is marketed under the brand Adempas® by Bayer HealthCare Pharmaceuticals. Treatment with riociguat costs USD $7,500 for 30 days of treatment.
Meprobamate
go.drugbank.com/drugs/DB00371ApprovedIllicitMeprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated).